• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人注意缺陷多动障碍的管理:重点关注盐酸哌甲酯。

Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.

机构信息

Baylor Family Medicine Residency at Garland, Garland, Texas, USA.

出版信息

Neuropsychiatr Dis Treat. 2009;5:421-32. doi: 10.2147/ndt.s4101. Epub 2009 Aug 20.

DOI:10.2147/ndt.s4101
PMID:19721722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2732009/
Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders in young adults and causes significant psychosocial impairment and economic burden to society. Because of the paucity of long-term evidence and lack of national guidelines for diagnosis and management of adult ADHD, most of the data are based on experience derived from management of childhood ADHD. This article reviews the current evidence for the diagnosis and management of adult ADHD with special emphasis on the role of methylphenidate hydrochloride preparations in its treatment. Methylphenidate hydrochloride, a stimulant that acts through the dopaminergic and adrenergic pathways, has shown more than 75% efficacy in controlling the symptoms of adult ADHD. Although concern for diversion of the drug exists, recent data have shown benefits in preventing substance use disorders in patients with adult ADHD.

摘要

注意缺陷多动障碍(ADHD)是青年人群中最常见的精神障碍之一,会给社会带来严重的心理社会损害和经济负担。由于缺乏长期证据和国家成人 ADHD 诊断和管理指南,大多数数据都基于从儿童 ADHD 管理中获得的经验。本文综述了成人 ADHD 的诊断和管理的现有证据,特别强调了盐酸哌甲酯制剂在治疗中的作用。盐酸哌甲酯是一种通过多巴胺能和肾上腺素能途径起作用的兴奋剂,在控制成人 ADHD 症状方面显示出超过 75%的疗效。虽然对药物滥用的担忧存在,但最近的数据显示,对成人 ADHD 患者使用该药物有预防物质使用障碍的益处。

相似文献

1
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.成人注意缺陷多动障碍的管理:重点关注盐酸哌甲酯。
Neuropsychiatr Dis Treat. 2009;5:421-32. doi: 10.2147/ndt.s4101. Epub 2009 Aug 20.
2
Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.成人注意缺陷多动障碍(ADHD)评估和管理的实用考虑因素。
Encephale. 2020 Feb;46(1):30-40. doi: 10.1016/j.encep.2019.06.005. Epub 2019 Oct 11.
3
[Supervised off-label prescribing of methylphenidate in adult ADHD].[成人注意力缺陷多动障碍中哌甲酯的监督下超说明书用药]
Encephale. 2019 Feb;45(1):74-81. doi: 10.1016/j.encep.2018.05.008. Epub 2018 Aug 16.
4
The potential for misuse and abuse of medications in ADHD: a review.注意力缺陷多动障碍(ADHD)药物的误用和滥用可能性:综述
Postgrad Med. 2014 Sep;126(5):64-81. doi: 10.3810/pgm.2014.09.2801.
5
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.托莫西汀:儿童及青少年注意力缺陷多动障碍用药综述
Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005.
6
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.从业者综述:自闭症谱系障碍儿童和青少年注意缺陷/多动障碍症状的药物治疗:系统评价和荟萃分析。
J Child Psychol Psychiatry. 2021 Jun;62(6):680-700. doi: 10.1111/jcpp.13305. Epub 2020 Aug 26.
7
Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.儿童及青少年注意力缺陷/多动障碍的诊断与治疗。美国医学协会科学事务委员会。
JAMA. 1998 Apr 8;279(14):1100-7. doi: 10.1001/jama.279.14.1100.
8
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.注意缺陷多动障碍:儿科药物治疗的最新进展。
Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.
9
Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.注意缺陷多动障碍儿童及青少年从神经兴奋剂治疗转换为托莫西汀治疗:临床方法及现有证据综述
Paediatr Drugs. 2008;10(1):39-47. doi: 10.2165/00148581-200810010-00005.
10
[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].[兴奋剂和非兴奋剂对成人注意力缺陷多动障碍(ADHD)的疗效与安全性]
Harefuah. 2011 Oct;150(10):788-90, 814.

引用本文的文献

1
Can attention-deficit/hyperactivity disorder be considered a form of cerebellar dysfunction?注意力缺陷多动障碍能被视为小脑功能障碍的一种形式吗?
Front Neurosci. 2025 Jan 22;19:1453025. doi: 10.3389/fnins.2025.1453025. eCollection 2025.
2
Arousal dysregulation and executive dysfunction in attention deficit hyperactivity disorder (ADHD).注意缺陷多动障碍(ADHD)中的觉醒调节障碍与执行功能障碍
Front Psychiatry. 2024 Jan 17;14:1336040. doi: 10.3389/fpsyt.2023.1336040. eCollection 2023.
3
Cognitive behavioural therapy in groups for medicated adults with attention deficit hyperactivity disorder: protocol for a randomised controlled trial.针对使用药物治疗的成人注意力缺陷多动障碍患者的团体认知行为疗法:一项随机对照试验的方案
BMJ Open. 2020 Oct 5;10(10):e037514. doi: 10.1136/bmjopen-2020-037514.
4
The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents.注意缺陷多动障碍对成年和青少年职业健康的负面影响。
Int Arch Occup Environ Health. 2012 Nov;85(8):837-47. doi: 10.1007/s00420-012-0794-0. Epub 2012 Jul 3.
5
High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report.高剂量哌甲酯治疗成人注意力缺陷多动障碍:一例报告
J Med Case Rep. 2012 May 14;6:125. doi: 10.1186/1752-1947-6-125.
6
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.阿齐碘代-N-苄基麦角酸二乙酰胺(利他林、专注达)衍生物:合理设计、合成、药理学评价及多巴胺转运体光亲和标记。
Bioorg Med Chem. 2011 Jan 1;19(1):504-12. doi: 10.1016/j.bmc.2010.11.002. Epub 2010 Nov 4.

本文引用的文献

1
Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review.抗抑郁药治疗成人注意缺陷多动障碍:系统评价。
Adv Ther. 2009 Feb;26(2):170-84. doi: 10.1007/s12325-009-0008-7. Epub 2009 Feb 23.
2
A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.一项针对患有注意力缺陷/多动障碍的成年人的低剂量缓释哌甲酯的随机、安慰剂对照、为期24周的研究。
Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22.
3
Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders.患有其他精神疾病的成人中未被识别的注意力缺陷/多动障碍
CNS Spectr. 2008 Nov;13(11):977-84. doi: 10.1017/s1092852900014036.
4
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.一项关于二甲磺酸赖右苯丙胺治疗成人注意力缺陷多动障碍有效性和安全性的双盲、安慰剂对照研究。
J Clin Psychiatry. 2008 Sep;69(9):1364-73. doi: 10.4088/jcp.v69n0903. Epub 2008 Sep 9.
5
Treatment of adults with attention-deficit/hyperactivity disorder.成人注意缺陷多动障碍的治疗。
Neuropsychiatr Dis Treat. 2008 Apr;4(2):389-403. doi: 10.2147/ndt.s6985.
6
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.托莫西汀治疗成人注意力缺陷多动障碍的长期开放标签安全性和疗效:一项4年研究的最终报告
J Atten Disord. 2008 Nov;12(3):248-53. doi: 10.1177/1087054708316250. Epub 2008 Apr 30.
7
Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.患有心脏病的儿童和青少年在接受治疗注意力缺陷多动障碍药物治疗时的心血管监测[已修正]:美国心脏协会青年先天性心脏病委员会心血管疾病理事会和心血管护理理事会的科学声明。
Circulation. 2008 May 6;117(18):2407-23. doi: 10.1161/CIRCULATIONAHA.107.189473. Epub 2008 Apr 21.
8
SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder.注意缺陷多动障碍中多巴胺转运体的单光子发射计算机断层扫描和正电子发射断层扫描
Expert Rev Neurother. 2008 Apr;8(4):611-25. doi: 10.1586/14737175.8.4.611.
9
Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study.兴奋剂治疗与成年男性注意力缺陷多动障碍患者后续物质使用障碍的风险:一项10年自然对照随访研究
Am J Psychiatry. 2008 May;165(5):597-603. doi: 10.1176/appi.ajp.2007.07091486. Epub 2008 Mar 3.
10
A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.一项针对患有注意力缺陷多动障碍的成年人,使用三种固定剂量的缓释口服渗透控释系统哌甲酯与安慰剂对照的随机试验。
Biol Psychiatry. 2008 May 15;63(10):981-9. doi: 10.1016/j.biopsych.2007.11.008. Epub 2008 Jan 22.